Riskpilot← Back to searchSign inGet full accessMiNA Therapeutics Denmark ApS
APSActiveCVR 43329545Frederikskaj 10B, 2.Manufacture of pharmaceutical preparations · NACE 2120Est. 20222 employees
Revenue 2024
DKK 4,7M
-58% vs 2023
EBITDA margin
10.8%
-93% vs 2023
Equity ratio
21.1%
Financial strength
Net profit 2024
DKK 373K
-94% vs 2023
| Revenue | DKK 4,7M | -58% |
| EBITDA | DKK 510K | -93% |
| Net profit | DKK 373K | -94% |
| Total assets | DKK 6,1M | +183% |
| Equity | DKK 1,3M | +41% |
| Employees | 2 | — |
Legal name
MiNA Therapeutics Denmark ApS
CVR number
43329545
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
15. juni 2022
Share capital
DKK 40.000
Employees
2 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af et bestyrelsesmedlem.
Company purpose
Selskabets formål er bedrive forskning og ydelse af tjenester til udvikling af humane lægemidler.
Address
Frederikskaj 10B, 2.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | -1.014 | 11.343 | 4.727 |
| Staff expenses | -4.729 | -4.461 | -4.217 |
| EBITDA | -5.743 | 6.882 | 510 |
| Depreciation & amort. | -9 | -8 | -7 |
| EBIT | -5.752 | 6.875 | 503 |
| Net financials | -1 | -3 | -18 |
| Profit before tax | -5.753 | 6.871 | 486 |
| Tax | -0 | 247 | 113 |
| Net profit | -5.753 | 6.624 | 373 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 400 | 2.142 | 6.069 |
| Equity | -5.713 | 911 | 1.284 |
| Long-term debt | 5.406 | 0 | 2.954 |
| Short-term debt | 707 | 1.231 | 1.831 |
| Total debt | 6.113 | 1.231 | 4.785 |
EBITDA margin
10.8%
This company
15.8%
Market median
-32% vs market
20222024
Equity ratio
21.1%
This company
38.2%
Market median
-45% vs market
20222024
Return on equity
29.0%
This company
18.4%
Market median
+58% vs market
20222024
Net profit margin
7.9%
This company
8.1%
Market median
-2% vs market
20222024
Asset turnover
0.78×
This company
1.12×
Market median
-30% vs market
20222024
Debt / equity
3.73×
This company
0.62×
Market median
-502% vs market
20222024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-06-15 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RS Management | Management | 2022 | — | — |
TK Management | Management | 2022 | — | — |
RJ Management | Management | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MiNA Therapeutics Denmark ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Robert Sebastian Habib | Management | 0 companies |
| Troels Koch | Management | 0 companies |
| Robin James Morrisson Wright | Management | 0 companies |
| Yael Gruenbaum Cohen | Board of Directors | 0 companies |
| Susan Clement Davies | Board of Directors | 0 companies |
| Norbert Wolfgang Bischofberger | Board of Directors | 0 companies |
| Robert Ian Lechler | Chairman | 0 companies |
| Peter James Jonathan Bains | Board of Directors | 0 companies |
| Stephanie Galantine-Heller | Board of Directors | 0 companies |
| Gur-Arye Yehuda Roshwalb | Board of Directors | 0 companies |
| Christopher Barry Wood | Board of Directors | 0 companies |
| Kieran Roy Darren Johnson | Board of Directors | 0 companies |
| Robert Charles Kopple | Board of Directors | 0 companies |
| Nagy Adly Habib | Chairman | 0 companies |